Genetic Epidemiological Evidence Indicates the Role of Lipid Control in Omega-3-Mediated Cardiovascular Protection

Jinhan **Yu**[1,#]; Chengjia **Li**[1,#]; Zipeng, **Liu**[2]; Yidan **Chen**[1]; Yao **Lei**[3]; Dingyang **Li**[1]; Wen **Ma**[4]; Yao **Wang**[5]; Yi **Yang**[6]; Renzhi **Wang**[1]; Yong-Fei **Wang**[1,*]

Author affiliations

1. School of Medicine, Warshel Institute for Computational Biology, The Second Affiliated Hospital, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.
2. Clinical Data Center, Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, China
3. Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China
4. School Board of Decision Sciences, The Hang Seng University of Hong Kong, Hong Kong, China
5. Department of Obstetrics and Gynaecology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
6. Department of Nephrology, Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, Zhejiang, China

#These authors contributed equally.

*Correspondence to: Yong-Fei Wang (yfwang@cuhk.edu.cn)

Abstract

Background: The association between omega-3 fatty acids and cardiovascular disease has been examined in populations with established disease. However, the definitive role of omega-3 fatty acids in cardiovascular risk remains inconclusive, and evidence from general populations is still limited. This study aims to examine the causal relationship between omega-3 and cardiovascular disease using large-scale genetic data.

Methods: We employed five well-established mendelian randomization (MR) methods to investigate the causal association between omega-3 and cardiovascular events. Two large independent omega-3 GWAS (>110,000 participants each) from general populations were analyzed across 14 cardiovascular and metabolic phenotypes (>50,000 participants each). To understand the direct effect of omega-3 on coronary artery disease (CAD), multivariable MR (MVMR) model and mediation analysis were conducted. Summary-data-based MR (SMR) was applied to identify circulating proteins associated with omega-3 levels.

Results: Genetically elevated omega-3 levels were found associated with increased cardiovascular risk across all MR methods, particularly for CAD (P_{median} = 2.65E-04), myocardial infarction (P_{median} = 1.03E-07) and heart failure (P_{median} = 4.84E-03). Higher genetically predicted omega-3 were linked to elevated LDL-C (P_{median} = 2.50E-33) and its key component apolipoprotein B (P_{median} = 5.60E-08), while reducing triglyceride levels (P_{median} = 4.16E-03). Notably, after adjusting for the genetic effect of LDL-C, omega-3 demonstrated a protective effect on CAD ($\beta_{combined}$ = -0.025, $P_{combined}$ = 0.022), which was strengthened by adjusting for both LDL-C and triglycerides. Mediation analysis suggests that omega-3 is likely to increase CAD risk through elevating LDL-C (P_{median} = 2.40E-12), highlighting the need for effective LDL-C management to maximize the cardiovascular benefits of omega-3. Circulating proteins, such as ANGPTL3 (P_{smr} = 1.22E-27) and PCSK9 (P_{smr} = 1.15E-21), were also found positively associated with omega-3 levels. A reanalysis of clinical trial data confirmed that the cardiovascular

benefits of omega-3 were closely related to the intensity of LDL-C lowering therapy.

Conclusions: Our results suggest that the cardiovascular benefits of omega-3 fatty acids may depend on effective lipid management, particularly LDL-C control. Combining omega-3 supplementation with advanced lipid-lowering therapy may be critical for maximizing their protective impact on cardiovascular health.

Keywords: Omega-3 fatty acid, lipid control, cardiovascular dieases, LDL-C, Mendelian randomization

Introduction

Omega-3 fatty acids, a type of polyunsaturated fatty acids (PUFAs), have long been investigated for their potential protective effects on cardiovascular health[1,2]. However, evidence from two large-scale randomized clinical trials (RCTs) remains inconclusive. The Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT, n = 8,179; NCT01492361) reported that high-dose icosapent ethyl (a purified and stable EPA ethyl ester, 4g/d) significantly reduced major cardiovascular events by 25% in patients with hypertriglyceridemia[3]. But concerns have been raised regarding the use of mineral oil as placebo. In contrast, the Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia (STRENGTH, n = 13,078; NCT02104817) trial found no significant cardiovascular benefit with omega-3 CA (a carboxylic acid formulation of EPA and DHA, 4g/d) compared to corn oil over a median follow-up of 42.0 months[4].

Previous studies were primarily conducted in populations with cardiovascular-related conditions[3,4], and the conflicting results demonstrated the challenges in investigating a clear causal relationship between omega-3 fatty acids and cardiovascular outcomes. These inconsistencies may result from placebo selection, drug use, dosing regimens, study populations, and the difficulty of controlling numerous confounding factors. Mendelian randomization (MR) offers a way to address these limitations by using genetic variants as instrumental variables (IVs) for exposures. This method reduces bias from potential confounders, as genetic variants are randomly allocated at conception and remain independent of most environmental and behavioral factors[5,6]. In addition, recent large-scale genome-wide associations studies (GWAS) of circulating metabolic traits[7-11] and cardiovascular diseases[12-18] provide valuable resources, offering a strong foundation for MR studies to explore the causal relationships between omega-3 levels and cardiovascular outcomes.

To date, at least 16 MR methods have been developed, with key differences in the selection of IVs, modeling, and techniques to control potential pleiotropy[19,20]. Among these, the inverse variance weighed (IVW) fixed-effects model remains the most widely used method. However, due to its higher susceptibility to type I error, MR-Egger[21], Weighted-mode[22], and MR-APSS[23] models were also incorporated in this study. These new methods have shown robust control of type I errors and improved accuracy in estimating causal effects under diverse conditions in both simulated and real-world data[20,24].

To ensure a robust causal inference, we integrated data from two large independent GWAS of circulating omega-3[9,25] with genetic data on 14 cardiovascular and metabolic phenotypes, each involving more than 50,000 participants (**Figure 1**). This study aims to systematically examine the causal relationships between omega-3 levels and cardiovascular risk using large-scale genetic data.

Methods

Study design and data sources

The full GWAS summary statistics used in this analysis were primarily obtained from the GWAS Catalog[26], with detailed information provided in **Table S1**. These GWAS were predominantly conducted in European populations. To ensure adequate statistical power, we included only studies with at least 50,000 participants. Patients or the public were not involved in the design, conduct, reporting, or dissemination plans of our research.

We collected two independent GWAS datasets for circulating omega-3 measurement as the exposure (**Figure 1**). The primary exposure dataset was derived from a multi-cohort meta-analysis, involving 136,016 participants[9], while the secondary exposure dataset was sourced from the UK Biobank, including 115,006 individuals[25]. Notably, there was no sample overlap between these two datasets, strengthening the validity of our findings. DHA measurements from the UK Biobank[25] were also included as the exposure. Summary statistics for other metabolic traits, including total cholesterol, low-

density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride, apolipoprotein B (ApoB), apolipoprotein A (ApoA)[7-10], were also mainly sourced from the two studies. Most participants in the multi-cohort study were fasted before blood collection[9], whereas the UK Biobank participants were generally non-fasted, with precise fasting intervals recorded and adjusted for in the analyses[25]. Both studies controlled for age, sex, fasting status, sample type, and relevant covariates, such as body mass index (BMI) and smoking status. These analytical strategies have been well validated and demonstrated in their publications[9,25].

We also collected GWAS summary statistics for a broad range of cardiovascular outcomes, including coronary artery disease (CAD)[12,14], myocardial infarction (n = 639,221)[13], heart failure (n = 977,323)[15], atrial fibrillation (n = 583,168)[16], stroke (n = 446.696)[17] , and its ischemic subtype (n = 440328)[17]. Two CAD GWAS datasets were analyzed: (i) a recent European meta-analysis with 181,522 cases and 1,165,690 controls[12], and (ii) the UK Biobank (34,541 cases and 261,984 controls)[14]. We also incorporated data for hypertension (n = 56,637)[11] and type 2 diabetes (T2D, n = 659,316)[18] due to their strong connection to cardiovascular disease, while type 1 diabetes (T1D, n = 173,981)[27], a type of autoimmune diseases, was included for comparison. Age, sex, principal components and relevant study-specific covariates were adjusted and validated in their publications.

We used the STROBE reporting guideline[28-30] to draft this manuscript, and the STROBE reporting checklist when editing, included in **Table S7.**

Instrumental variable selection

Common SNPs (minor-allele frequency > 1 %) associated with omega-3 levels at genome-wide significance level (P < 5.00E-08) were selected. Correlated variants were then removed by linkage disequilibrium (LD) clumping (1-Mb window, $r^2 < 0.05$) based on the 1,000 Genomes European panel. To mitigate pleiotropic SNPs, we further applied Steiger filtering[31] discarding SNPs that explained more variance in the outcome than in the exposure, maintaining the correct causal direction.

Mendelian randomization analyses

To ensure the robustness of our MR results, we employed four well-established MR algorithms, as evaluated in previous studies[19,20]. These included: (i) IVW Fixed-effects[32], (ii) MR-Egger[21], (iii) Weighted Mode[22], and (iv) APSS[33]. In addition, given that the *FADS* variant accounts for a large proportion of variance in omega-3 levels[34], we performed a single-variant Wald Ratio analysis[35] using rs174564 or a proxy SNP in strong LD ($r^2 > 0.9$). A causal association was accepted when at least three of the five tests yielded statistically significant results with consistent directional effects. The significance threshold for *P* values was adjusted using Bonferroni correction.

To ensure comparability between datasets, we standardized the SNP-effect estimates and their standard errors (SE). Each raw effect (β) was divided by its SE to create a Z-score, which we then rescaled by $\sqrt{n}$ (n = sample size) to produce a unit-free effect ($Z/\sqrt{n}$). The corresponding SE was set to $1/\sqrt{n}$. This transformation eliminates differences in measurement units and variance across studies, ensuring that subsequent instrumental-variable analyses are conducted on a consistent scale.

SNP-exposure and SNP-outcome datasets were harmonized using the TwoSampleMR package (version 0.5.11)[36]. IVW Fixed-effects model, MR-Egger, Weighted Mode, and Wald Ratio analyses were also conducted using this package. APSS was implemented with the MRAPSS package (0.0.0.9), which restricted the analysis to SNPs in the HapMap 3 reference panel. The background parameters were estimated by LD score regression[37], with the LD score calculated from the 1,000 Genomes European panel.

Multivariable mendelian randomization analysis

Multivariable mendelian randomization (MVMR) analysis was performed using the TwoSampleMR package (version 0.5.11) to estimate the direct association of omega-3 levels with CAD. The models were sequentially adjusted for LDL-C, triglycerides and then for both together. IVs for omega-3 fatty acids, LDL-C, and triglycerides were selected independently based on predefined criteria. LD clumping (1-Mb window, $r^2 < 0.05$) was subsequently

conducted to ensure instrument independence. Effect alleles were harmonized across both exposures and the outcome datasets.

Mediation analysis

Mediation analysis[38] was applied to partition the effect of genetically predicted omega-3 on the CAD into a direct and an indirect effect mediated through LDL-C. The total effect was estimated using the four well established MR algorithms, respectively. Indirect effects were assessed using a two-step MR framework (**Figure 4b**): (1) estimating the effect of omega-3 on LDL-C (β_{step1}), and (2) estimating the effect of LDL-C on CAD (β_{step2}). The indirect effect was then calculated using the product method as $\beta_{step1} \times \beta_{step2}$[39,40].

To estimate the SE of the indirect effect, we applied two approaches: (1) the Delta method approximates the variance using the delta rule, yielding a closed-form solution ($SE_{indirect} = sqrt(\beta_{step1}^2 * SE_{step2}^2 + \beta_{step2}^2 * SE_{step1}^2)$)[41] but potentially underestimating variability when coefficient distributions are skewed; (2) the Monte Carlo (MC) method generated empirical confidence intervals by repeatedly sampling[42], offering greater robustness at the expense of higher computational cost. Both methods were implemented to ensure robustness of our inference.

Protein quantitative trait loci data analysis

Summary-data-based mendelian randomization (SMR)[43,44] was applied to identify plasma proteins associated with omega-3 levels. To differentiate true associations from those arising due to LD, we incorporated the heterogeneity in dependent instruments (HEIDI) test[44]. These analyses were conducted using the SMR portal[43], leveraging protein quantitative trait loci (pQTL) summary statistics obtained from the Fenland study (n = 10,708)[45]. Associations were considered statistically significant if they met the following criteria: (i) the lead SNP in omega-3 GWAS passed the genome-wide significant threshold (P < 5.00E-08); (ii) the SMR test passed a Bonferroni-corrected threshold (P_{SMR} < 2.59E-05; 0.05/1,927); and (iii) there was no evidence of horizontal pleiotropy due to LD (P_{HEIDI} > 0.01). Proteins were considered associated with omega-3 if significant associations were

226 confirmed in both omega-3 GWAS. Gene set enrichment analysis was
227 conducted using ToppGene Suite[46]. Regional plots were generated by R
228 package locuscomparer (Version 1.0.0)[47].

229 Results

230 Genetically elevated omega-3 levels increase the risk of 231 cardiovascular outcomes

232 Summary statistics from a GWAS of omega-3 measure in 136,016
233 participants[9] were used as the primary exposure dataset. The causal effects
234 on seven cardiovascular-related outcomes were examined using five MR
235 estimates (**Methods**). A causal association was considered robust when at
236 least three methods showed consistent effect directions and met the
237 Bonferroni-corrected significance threshold ($P < 0.00625$; 0.05/8).

238 Our analysis showed that genetically elevated omega-3 levels have a
239 significant causal effect on the risk of CAD (P_{median} = 2.65E-04), with
240 consistent effect directions across all MR estimates (**Figure 2a**). These
241 results were consistent when using the CAD GWAS exclusively from the UK
242 Biobank (P_{median} = 2.87E-07). Similar causal relationships were observed for
243 myocardial infarction (P_{median} = 1.03E-07) and heart failure (P_{median} = 4.84E-03).
244 We also observed modest effects of omega-3 on the risk of atrial fibrillation
245 (P_{median} =0.041), stroke (P_{median} = 0.038) and its ischemic subtype (P_{median} =
246 0.035). Although these associations did not meet the Bonferroni-corrected
247 significance threshold, the directions of causal effects were consistent across
248 all five MR estimates. In comparison, no causal effects were observed for T2D
249 (P_{median} = 0.139) and T1D (P_{median} = 0.297).

250 We repeated the analysis using the secondary omega-3 GWAS from UK
251 Biobank. The results confirmed the causal association of increased omega-3
252 levels with higher risks of CAD (P_{median} = 2.94E-03 and 5.45E-05 for
253 respective datasets), myocardial infarction (P_{median} = 1.27E-03) and heart
254 failure (P_{median} = 4.60E-03). All five MR estimates pointed in the same direction
255 (**Figure S1a**). The positive association with atrial fibrillation (P_{median} = 0.065),

256 stroke (P_{median} = 0.140), and ischemic stroke (P_{median} = 0.044) still exists,
257 whereas no associations were detected for T2D (P_{median} = 0.126) and T1D
258 (P_{median} = 0.727). We also repeated the analyses using a GWAS of DHA as
259 the exposure. The results were highly consistent, demonstrating a significant
260 causal effect of elevated DHA levels on the risks of cardiovascular outcomes
261 (**Figure S2**).

262 We next conducted sensitivity analyses by excluding genetic variants in the
263 *FADS* gene cluster (hg19; chr11:61,067,097–62,134,826), as the fatty acid
264 desaturases encoded in this region directly involve omega-3 metabolism[48].
265 The causal association with CAD (P_{median} = 9.47E-08 and 8.39E-07 for
266 respective datasets), myocardial infarction (P_{median} = 5.70E-06) and heart
267 failure (P_{median} = 0.016) remained significant and directionally consistent
268 (**Figure 3a**). These findings were consistent in the secondary omega-3 GWAS
269 (**Figure 3b**).

270 Reverse MR analyses were also conducted using genetic variants associated
271 with cardiovascular outcomes as IVs. No evidence of reverse causal
272 associations was observed (**Figure S3**), suggesting a unidirectional
273 relationship in which omega-3 levels influence cardiovascular outcomes.
274 Taken together, our results suggest that elevated omega-3 levels may
275 increase cardiovascular risk, particularly CAD, myocardial infarction, and
276 heart failure.

277 Omega-3 elevates LDL-C while lowering triglycerides

278 We further examined the causal influence of omega-3 fatty acids on related
279 metabolic traits. Similarly, a causal association was considered robust if at
280 least three methods showed consistent directions and met the Bonferroni-
281 corrected significance threshold (P < 0.0071; 0.05/7).

282 Our analyses indicated that genetically elevated omega-3 levels significantly
283 increased total cholesterol (P_{median} = 7.40E-33), especially LDL-C (P_{median} =
284 2.50E-33). These results were highly consistent across the five MR methods
285 (**Figure 2b**). In contrast, no significant effect was observed for HDL-C (P_{median}
286 = 0.079) and hypertension (P_{median} = 0.215). This pattern extended to key

287 apolipoproteins, with a significant effect found on ApoB (P_{median} = 5.60E-08),
288 the key component of LDL particles, while no association was found for ApoA
289 (P_{median} = 0.276), the key component of HDL particles. The causal effects on
290 LDL-C and ApoB were also replicated using another independent omega-3
291 GWAS from UK Biobank (**Figure S1b**). Sensitivity analyses were also
292 performed by excluding genetic variants within the *FADS* gene cluster. Strong
293 positive causal associations of omega-3 with LDL-C and ApoB levels were still
294 observed (**Figure S4**).

295 To address potential influence of horizontal pleiotropy between omega-3 and
296 LDL-C mentioned in previous studies[49], we adopted more stringent criteria for
297 selecting IVs. Only genetic variants associated with omega-3 levels (P <
298 5.00E-08) but not associated with LDL-C levels (P > 0.05), were included in
299 the MR analyses. Despite the reduced statistical power, a positive causal
300 association between omega-3 and LDL-C remained evident *(P* < 0.019;
301 **Figure S5**).

302 In addition to LDL-C, our analyses demonstrated that genetically elevated
303 omega-3 levels significantly lowered triglycerides (P_{median} = 4.16E-03). This
304 result was also confirmed by another triglyceride GWAS data[8] (P_{median} =
305 6.80E-04; **Figure 2b**). A consistent direction of effect on triglyceride lowering
306 was also observed when utilizing the omega-3 GWAS derived from UK
307 Biobank as the exposure (**Figure S1b**). These findings align with the
308 American Heart Association (AHA)'s recommendation of omega-3 for
309 reducing triglycerides[50]

310 However, exclusion of genetic variants within the *FADS* gene cluster reversed
311 this association in a positive direction. This result was further validated using
312 the secondary omega-3 GWAS data (**Figure S4**), highlighting the complex
313 role of omega-3 in triglyceride reduction. Specifically, the triglyceride-lowering
314 effect could be primarily mediated through fatty acid desaturase activity, while
315 omega-3-associated variants outside the *FADS* cluster were linked to
316 increased triglyceride levels. These findings suggest that the effectiveness of
317 omega-3 supplementation in reducing triglycerides may depend on an
318 individual's fatty acid desaturase activity.

319 To validate these findings, we revisited data from previous clinical trials. To
320 minimize the influence of cholesterol-lowering drugs, we first analyzed data
321 from the Comparing EPA to DHA trial (ComparED; NCT01810003)[51], which
322 assessed changes in blood lipids following EPA or DHA intake among adults
323 without a history of cardiovascular disease[51]. Compared to corn oil, both EPA
324 and DHA significantly increased LDL-C levels while reducing triglycerides.
325 This effect was markedly stronger with DHA, demonstrating a mean LDL-C
326 increase of 0.16 mmol/L (P < 0.0001) and a mean triglyceride reduction of
327 0.25 mmol/L (P < 0.0001) over a 10-week follow-up[51].

328 Next, we revisited data from the STRENGTH trial[4]. Although all participants
329 were on statin therapy, those in the omega-3 CA group still showed a
330 significant increase in LDL-C compared with the corn oil group (geometric
331 mean ratio = 1.03; P < 0.001) and a substantial reduction in triglyceride levels
332 (geometric mean ratio = 0.82; P < 0.001)[4].

333 We also investigated data from the REDUCE-IT trial[3]. Due to the use of
334 mineral oil as the control, between-group comparisons were not considered.
335 As all participants were receiving statin therapy, LDL-C were expected to be
336 reduced[52]. However, within the icosapent ethyl group, LDL-C levels increased
337 by 3.1 % from the baseline (P < 0.001). Triglycerides decreased by 18.3 % (P
338 < 0.001) following 12 months of treatment. Collectively, findings from previous
339 clinical trials supported our MR results that omega-3 fatty acids can elevate
340 LDL-C levels while lowering triglycerides.

341 The protective effect of omega-3 on CAD depends on lipid 342 control

343 To evaluate the impact of LDL-C, we estimated the effect of omega-3 on
344 cardiovascular outcome by controlling LDL-C-associated variants using
345 MVMR algorithm (**Methods**). To maximize statistical power, CAD was
346 selected as the outcome due to its largest sample size and the availability of
347 additional CAD dataset for replication. Our results showed that, after adjusting
348 for LDL-C's genetic contribution, the effect of omega-3 on CAD became
349 protective. The association remained consistent when replicated using the

350 secondary omega-3 GWAS or an alternative CAD GWAS, yielding a
351 combined effect estimate of approximately -0.025 ($P_{combined}$ = 0.0225) (**Figure**
352 **4a** and **Table S2**). In contrast, adjusting for the genetic variants associated
353 with triglycerides didn't change the direction of the associations (**Figure 4a**
354 and **Table S3**). However, we found that adjusting for the genetic effects of
355 both LDL-C and triglycerides further strengthened omega-3's protective
356 association with CAD ($\beta_{combined}$ = -0.066, $P_{combined}$ = 1.28E-11; **Figure 4a** and
357 **Table S4**). These findings highlight the critical role of lipid control, particularly
358 LDL-C, in optimizing the cardioprotective effects of omega-3.

359 To further evaluate the role of LDL-C in mediating the effect of omega-3 fatty
360 acids on CAD risk, we utilized mediation analysis to decompose the total
361 effect into direct and indirect components (**Methods**). The indirect effect on
362 CAD through LDL-C was significant (β_{median} = 0.031; P_{median} = 2.40E-12;
363 **Figure 4b**), explaining approximately 38.0–81.9% of the total effect across
364 four MR estimates (**Figure 4b** and **Table S5**). These results remained robust
365 when replicated using an alternative CAD GWAS (**Figure S6** and **Table S5**).
366 These findings suggest LDL-C as a major mediator of the association
367 between elevated omega-3 and CAD risk and highlight the potential
368 importance of targeting LDL-C reduction in this pathway.

369 To validate the significance of LDL-C management in optimizing omega-3
370 benefits, we reanalyzed data from the STRENGTH and REDUCE-IT trials,
371 both of which evaluated the effect of high-dose omega-3 on cardiovascular
372 events[3,4]. Subgroup analyses support our findings (**Figure 4c)**. In STRENGTH,
373 compared to corn oil, omega-3 CA appeared more effective in participants
374 receiving high-intensity statin therapy (Hazard Ratio [HR] = 0.94) than in other
375 participants (HR = 1.04), though this difference did not reach statistical
376 significance (P = 0.28). Notably, in participants receiving combined statin and
377 ezetimibe therapy, a regimen that achieves greater LDL-C reduction, omega-3
378 CA significantly lowered cardiovascular risk compared to corn oil (HR = 0.54,
379 95% Confidence Interval [CI]: 0.34-0.86; P = 0.0094)[53].

380 A similar trend was observed in the REDUCE-IT trial, where icosapent ethyl
381 conferred a significant cardiovascular benefit over mineral oil among

382 participants receiving high-intensity statin therapy (HR = 0.69, 95% CI: 0.58–
383 0.82; *P* = 2.60E-05). In contrast, no benefit was seen in the low-intensity statin
384 group (HR = 1.12, 95% CI: 0.74–1.69; *P* = 0.59). The difference between the
385 two groups was significant (Cochran's Q, *P* = 0.034), indicating that patients
386 on high-intensity statin therapy gained substantially more from icosapent ethyl
387 than those on low-intensity therapy. In the smaller subgroup receiving both a
388 statin and ezetimibe, icosapent ethyl also suggested a protective effect (HR =
389 0.82; 95% CI, 0.57–1.16), although this was not significantly different from the
390 statin-only group. This may be due to the limited sample size and the fact that
391 93% of participants were already on at least moderate-intensity statin therapy[3].
392 Taken toghether, our findings suggest the importance of lowering LDL to
393 optimize the cardioprotective effects of omega-3. However, the potential for
394 enhanced benefits through concurrent management of triglycerides and LDL-
395 C requires further validation.

396 Plasma proteins associated with omega-3 levels

397 Circulating proteins are often used as biomarkers or targets for
398 pharmacological intervention[45]. We incorporated pQTL data from the Fenland
399 study (n = 10,708) to detect plasma proteins associated with omega-3 levels.
400 Using SMR analysis combined with the HEIDI test (**Methods**), we identified 9
401 candidate proteins that passed the Bonferroni-corrected threshold (P_{SMR} <
402 2.59E-05; 0.05/1,927). Of these, five were further replicated in the secondary
403 omega-3 GWAS data (**Figure 5**), including Glucokinase Regulator (GCKR),
404 Angiopoietin Like 3 (ANGPTL3), Proprotein Convertase Subtilisin/Kexin Type
405 9 (PCSK9), T Cell Immunoglobulin And Mucin Domain Containing 4 (TIMD4),
406 and ApoB (**Table S6**). Regional plots revealed that genetic variants linked to
407 the expression of these proteins well colocalized with signals for omega-3
408 levels (**Figure S7 - S8**), highlighting strong associations between these
409 circulating proteins and omega-3 metabolism.

410 Gene set enrichment analysis demonstrated that these proteins were highly
411 enriched in pathways related to lipid homeostasis (GO:0055088; FDR =
412 1.91E-04) and triglyceride metabolic process (GO:0006641; FDR = 2.04E-04).
413 Of these, ANGPTL3 (β_{SMR} = 0.197, P_{SMR} = 1.22E-27 and P_{HEIDI} = 0.898),

PCSK9 (β_{SMR} = 0.192, P_{smr} = 1.15E-21 and P_{HEIDI} = 0.119), and ApoB (β_{SMR} = 0.488, P_{smr} = 1.57E-10 and P_{HEIDI} = 0.153) demonstrated a positive correlation with omega-3 levels (**Figure 5**). Their upregulations have been found linked to increased LDL-C levels and a higher risk of cardiovascular events[54-56]. These genetic findings suggest a potential mechanism whereby higher omega-3 levels are positively associated with proteins known to increase LDL-C (PCSK9, ANGPTL3, ApoB), which could partly explain their potential link to increased cardiovascular risk. However, this hypothesis requires further mechanistic studies and clinical validation.

Notably, PCSK9 and ANGPTL3 are established targets for FDA-approved drugs. Evolocumab, a PCSK9 inhibitor, has been shown to reduce LDL-C levels by 59% compared to placebo at 48 weeks[57], while Evinacumab, an ANGPTL3 inhibitor, achieves a 49% reduction in LDL-C and approximately 50% reductions in triglyceride levels relative to placebo at 24 weeks in patients with familial hypercholesterolemia[58]. In light of the MVMR and mediation analyses, omega-3 supplementation could be a valuable complement to PCSK9-targeted and ANGPTL3-targeted therapies. These hypotheses warrant further investigation.

Discussion

Using large-scale genetic data, we showed that genetically elevated omega-3 levels were associated with increased cardiovascular risk, particularly CAD, myocardial infarction, and heart failure. These results were consistent across independent omega-3 GWAS datasets and different MR algorithms. Additional sensitivity analyses also supported the positive causal relationship between higher omega-3 levels and increased cardiovascular risk. Although prior studies, such as STRENGTH and REDUCE-IT, reported neutral or protective effects, our results don't violate their findings, as these studies were conducted in patients receiving LDL-lowering therapy. Our MVMR and mediation analyses showed that effective LDL control is essential for omega-3 to confer cardiovascular benefits, providing a plausible explanation for the differing results between the disease population and the general population.

445 Notably, a recent prospective cohort study showed that regular use of fish oil
446 supplements was linked to a higher risk of first-time heart disease in
447 individuals without prior cardiovascular conditions, but slowed disease
448 progression in those with existing cardiovascular disease[59]. The differences
449 may also reflect the role of LDL control in mediating the protective effect of
450 omega-3, as individuals without cardiovascular conditions often use omega-3
451 supplementation without concurrent LDL-lowering therapy. Emerging
452 evidence[60] also suggests that LDL-C may act as a mediating factor between
453 increased fatty acids biosynthesis and higher cardiovascular risk. Consistent
454 with these findings, further analyses from the STRENGTH[4] and REDUCE-IT[3]
455 trials indicate that the protective effect of omega-3 on CAD is more
456 pronounced with intensive LDL-C-lowering therapy. Together, these findings
457 highlight the need for optimal lipid management, particularly LDL-C, when
458 using omega-3 supplementation to achieve cardiovascular protection.

459 Analysis of metabolic traits revealed that elevated omega-3 levels were
460 significantly linked to increased LDL-C, ApoB, and total cholesterol levels.
461 Circulating proteins known to increase LDL-C, such as PCSK9, ANGPTL3,
462 ApoB, were also found positively associated with omega-3 levels. These
463 findings well explain the positive association observed between omega-3 and
464 cardiovascular risk. However, mechanistic studies are needed to clarify the
465 underlying pathways. Omega-3 also showed a triglyceride-lowering effect,
466 though this benefit appeared to be mainly driven by the *FADS* gene cluster.
467 Previous clinical trials, including ComparED, STRENGTH and REDUCE-IT,
468 also support these findings.

469 Additionally, PCSK9 and ANGPTL3 are established targets of approved lipid-
470 lowering drugs[61,62]. Their positive associations with omega-3 levels raise the
471 possibility that omega-3 supplementation may interact with these pathways.
472 Further clinical studies are needed to assess whether combining omega-3
473 with therapies targeting PCSK9 or ANGPTL3 could enhance cardiovascular
474 benefits.

475 We acknowledge that MR methods rely on strong assumptions[23,63]. The
476 selection of valid IVs is crucial for producing reliable results. We restricted the

477 analyses to GWAS with large sample size (n > 50,000) and applied Steiger
478 filtering to exclude potential pleiotropy. Multiple well-established MR methods
479 were also utilized in combination to further enhance the reliability of the
480 findings. Despite these, completely ruling out horizontal pleiotropy and
481 ensuring sufficient statistical power remain challenging. In addition, some MR
482 analyses were conducted based on a one-sample test, where both exposure
483 and outcomes were collected from the same source, such as the UK Biobank.
484 This approach can minimize differences in population ancestry and
485 composition, but it is more susceptible to overfitting and weak instrument
486 bias[64].

487 In summary, this study suggests that the cardiovascular benefits of omega-3
488 fatty acids may depend on effective lipid management, particularly LDL-C
489 control. We hypothesize that combining omega-3 supplementation with
490 effective lipid-lowering therapy may help maximize cardiovascular benefit, a
491 concept that warrants further clinical investigation.

492 Conclusion

493 Our results suggest that the cardiovascular benefits of omega-3 fatty acids
494 are context-dependent, showing protective effects when lipids, particularly
495 LDL-C, are well controlled. We hypothesize that combining omega-3
496 supplementation with effective lipid-lowering therapy may help optimize
497 cardiovascular benefit, a concept that warrants further clinical investigation.

498 List of abbreviations

499 CAD : Coronary artery disease

500 MVMR : Multivariable Mendelian randomization

501 SMR : Summary-data-based Mendelian randomization

502 PUFAs : Polyunsaturated fatty acids

503 RCTs : Randomized clinical trials

MR：Mendelian randomization

IVs：Instrumental variables

GWAS：Genome-wide association studies

IVW：Inverse variance weighted

LDL-C：Low-density lipoprotein cholesterol

HDL-C：High-density lipoprotein cholesterol

ApoB：Apolipoprotein B

ApoA：Apolipoprotein A

BMI：Body mass index

T2D：Type 2 diabetes

T1D：Type 1 diabetes

LD：Linkage disequilibrium

SE：Standard errors

HEIDI：Heterogeneity in dependent instruments test

pQTL：Protein quantitative trait loci

Acknowledgments

We gratefully acknowledge funding supports from the Shenzhen-Hong Kong Jointly Funded Project (Category A; SGDX20230116093201002) and the Stability Support for Higher Education from Shenzhen Science and Technology Program, the Guangdong Natural Science Foundation Youth Enhancement Project (2024A1515030287), 1+1+1 CUHK-CUHK(SZ)-GDSTC Joint Collaboration Fund (GRDP2025-056 and YSP05) and the National Natural Science Foundation of China (82471825). We also extend our thanks to the faculty development grant (Project number: H800005) from the Hang Seng University of Hong Kong and the Warshel Institute for Computational Biology and their funding support from Shenzhen City and Longgang District (LGKCSDPT2024001). The authors thank the anonymous reviewers for their

constructive comments and valuable suggestions that helped to improve the quality of the manuscript.

Author contributions

Y.-F. Wang conceived the study. J.-H. Yu and C.-J. Li took the lead in data analysis. J.-H. Yu, C.-J. Z. Liu, Li, Y.-D. Chen, Y. Lei, D.-Y. Li, W. Ma, Y. Wang, Y. Yang, and R. Wang collected GWAS summary data. J.-H. Yu, C.-J. Li, Y. Wang, Y. Yang, R. Wang, and Y.-F. Wang contributed to the interpretation of the findings. J.-H. Yu, C.-J. Li and Y.-F. Wang wrote the manuscript. All authors read and contributed to the manuscript.

Competing interests

The authors declare no competing interests.

Role of study sponsors

The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data availability

See **Table S1**.

Declaration of generative AI

We cautiously used ChatGPT 4.1 for linguistic and grammatical refinement to improve the readability during the proofreading. After using this tool, the authors reviewed and edited the content as needed and took full responsibility for the content of the publication.

555 # References

556 1. Jayedi A, Shab-Bidar S. Fish Consumption and the Risk of Chronic Disease:
557 An Umbrella Review of Meta-Analyses of Prospective Cohort Studies. *Adv Nutr*. Sep
558 1 2020;11(5):1123-1133. doi:10.1093/advances/nmaa029

559 2. Del Gobbo LC, Imamura F, Aslibekyan S, et al. omega-3 Polyunsaturated
560 Fatty Acid Biomarkers and Coronary Heart Disease: Pooling Project of 19 Cohort
561 Studies. *JAMA Intern Med*. Aug 1 2016;176(8):1155-66.
562 doi:10.1001/jamainternmed.2016.2925

563 3. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with
564 Icosapent Ethyl for Hypertriglyceridemia. *The New England journal of medicine*. Jan
565 3 2019;380(1):11-22. doi:10.1056/NEJMoa1812792

566 4. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty
567 Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High
568 Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. *JAMA*.
569 2020;324(22):2268-2280. doi:10.1001/jama.2020.22258

570 5. Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and
571 Scope. *Cold Spring Harb Perspect Med*. Jan 4
572 2022;12(1)doi:10.1101/cshperspect.a040501

573 6. Bowden J, M FDG, Minelli C, Smith GD, Sheehan NA, Thompson JR.
574 Assessing the suitability of summary data for two-sample Mendelian randomization
575 analyses using MR-Egger regression: the role of the I^2 statistic. *International Journal*
576 *of Epidemiology*. 2016/12;45(6)doi:10.1093/ije/dyw220

577 7. Graham SE, Clarke SL, Wu KH, et al. The power of genetic diversity in
578 genome-wide association studies of lipids. *Nature*. Dec 2021;600(7890):675-679.
579 doi:10.1038/s41586-021-04064-3

580 8. Koskeridis F, Evangelou E, Said S, et al. Pleiotropic genetic architecture and
581 novel loci for C-reactive protein levels. *Nat Commun*. Nov 14 2022;13(1):6939.
582 doi:10.1038/s41467-022-34688-6
583 9. Karjalainen MK, Karthikeyan S, Oliver-Williams C, et al. Genome-wide
584 characterization of circulating metabolic biomarkers. *Nature*. Apr
585 2024;628(8006):130-138. doi:10.1038/s41586-024-07148-y
586 10. Sinnott-Armstrong N, Tanigawa Y, Amar D, et al. Genetics of 35 blood and
587 urine biomarkers in the UK Biobank. *Nat Genet*. Feb 2021;53(2):185-194.
588 doi:10.1038/s41588-020-00757-z
589 11. Guindo-Martinez M, Amela R, Bonas-Guarch S, et al. The impact of non-
590 additive genetic associations on age-related complex diseases. *Nat Commun*. Apr 23
591 2021;12(1):2436. doi:10.1038/s41467-021-21952-4
592 12. Aragam KG, Jiang T, Goel A, et al. Discovery and systematic characterization
593 of risk variants and genes for coronary artery disease in over a million participants.
594 *Nat Genet*. Dec 2022;54(12):1803-1815. doi:10.1038/s41588-022-01233-6
595 13. Hartiala JA, Han Y, Jia Q, et al. Genome-wide analysis identifies novel
596 susceptibility loci for myocardial infarction. *Eur Heart J*. Mar 1 2021;42(9):919-933.
597 doi:10.1093/eurheartj/ehaa1040
598 14. van der Harst P, Verweij N. Identification of 64 Novel Genetic Loci Provides
599 an Expanded View on the Genetic Architecture of Coronary Artery Disease. *Circ Res*.
600 Feb 2 2018;122(3):433-443. doi:10.1161/CIRCRESAHA.117.312086
601 15. Shah S, Henry A, Roselli C, et al. Genome-wide association and Mendelian
602 randomisation analysis provide insights into the pathogenesis of heart failure. *Nat*
603 *Commun*. Jan 9 2020;11(1):163. doi:10.1038/s41467-019-13690-5

604 16. Roselli C, Chaffin MD, Weng LC, et al. Multi-ethnic genome-wide
605 association study for atrial fibrillation. *Nat Genet*. Jun 11 2018;50(9):1225-1233.
606 doi:10.1038/s41588-018-0133-9
607 17. Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association
608 study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes.
609 *Nat Genet*. Apr 2018;50(4):524-537. doi:10.1038/s41588-018-0058-3
610 18. Xue A, Wu Y, Zhu Z, et al. Genome-wide association analyses identify 143
611 risk variants and putative regulatory mechanisms for type 2 diabetes. *Nat Commun*.
612 Jul 27 2018;9(1):2941. doi:10.1038/s41467-018-04951-w
613 19. Boehm FJ, Zhou X. Statistical methods for Mendelian randomization in
614 genome-wide association studies: A review. *Comput Struct Biotechnol J*.
615 2022;20:2338-2351. doi:10.1016/j.csbj.2022.05.015
616 20. Hu X, Cai M, Xiao J, et al. Benchmarking Mendelian randomization methods
617 for causal inference using genome-wide association study summary statistics. *Am J*
618 *Hum Genet*. Aug 8 2024;111(8):1717-1735. doi:10.1016/j.ajhg.2024.06.016
619 21. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
620 instruments: effect estimation and bias detection through Egger regression. *Int J*
621 *Epidemiol*. Apr 2015;44(2):512-25. doi:10.1093/ije/dyv080
622 22. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data
623 Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol*.
624 Dec 1 2017;46(6):1985-1998. doi:10.1093/ije/dyx102
625 23. Hu X, Zhao J, Lin Z, et al. Mendelian randomization for causal inference
626 accounting for pleiotropy and sample structure using genome-wide summary statistics.
627 *Proc Natl Acad Sci U S A*. Jul 12 2022;119(28):e2106858119.
628 doi:10.1073/pnas.2106858119

629 24. Slob EAW, Burgess S. A comparison of robust Mendelian randomization
630 methods using summary data. *Genet Epidemiol*. Jun 2020;44(4):313-329.
631 doi:10.1002/gepi.22295
632 25. Richardson TG, Leyden GM, Wang Q, et al. Characterising metabolomic
633 signatures of lipid-modifying therapies through drug target mendelian randomisation.
634 *PLoS Biol*. Feb 2022;20(2):e3001547. doi:10.1371/journal.pbio.3001547
635 26. Cerezo M, Sollis E, Ji Y, et al. The NHGRI-EBI GWAS Catalog: standards
636 for reusability, sustainability and diversity. *Nucleic Acids Res*. Jan 6
637 2025;53(D1):D998-D1005. doi:10.1093/nar/gkae1070
638 27. Crouch DJM, Inshaw JRJ, Robertson CC, et al. Bayesian Effect Size Ranking
639 to Prioritise Genetic Risk Variants in Common Diseases for Follow-Up Studies.
640 *Genet Epidemiol*. Jan 2025;49(1):e22608. doi:10.1002/gepi.22608
641 28. The Strengthening the Reporting of Observational Studies in Epidemiology
642 (STROBE) Statement: Guidelines for Reporting Observational Studies. *Annals of*
643 *Internal Medicine*. 2007;147(8):573-577. doi:10.7326/0003-4819-147-8-200710160-
644 00010 %m 17938396
645 29. Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the
646 reporting of observational studies in epidemiology using mendelian randomisation
647 (STROBE-MR): explanation and elaboration. *BMJ*. Oct 26 2021;375:n2233.
648 doi:10.1136/bmj.n2233
649 30. Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the
650 Reporting of Observational Studies in Epidemiology Using Mendelian Randomization:
651 The STROBE-MR Statement. *JAMA*. 2021;326(16):1614-1621.
652 doi:10.1001/jama.2021.18236

653 31. Hemani G, Tilling K, Smith GD. Orienting the causal relationship between
654 imprecisely measured traits using GWAS summary data. *PLOS Genetics*.
655 2017;13(11)doi:10.1371/journal.pgen.1007081
656 32. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis
657 with multiple genetic variants using summarized data. *Genet Epidemiol*. Nov
658 2013;37(7):658-65. doi:10.1002/gepi.21758
659 33. Cinelli C, LaPierre N, Hill BL, Sankararaman S, Eskin E. Robust Mendelian
660 randomization in the presence of residual population stratification, batch effects and
661 horizontal pleiotropy. *Nat Commun*. Mar 1 2022;13(1):1093. doi:10.1038/s41467-
662 022-28553-9
663 34. Guan W, Steffen BT, Lemaitre RN, et al. Genome-wide association study of
664 plasma N6 polyunsaturated fatty acids within the cohorts for heart and aging research
665 in genomic epidemiology consortium. *Circ Cardiovasc Genet*. Jun 2014;7(3):321-331.
666 doi:10.1161/CIRCGENETICS.113.000208
667 35. Wald A. The Fitting of Straight Lines if Both Variables are Subject to Error.
668 *The Annals of Mathematical Statistics*. 1940;11(3):284-300, 17.
669 36. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports
670 systematic causal inference across the human phenome. *Elife*. May 30
671 2018;7doi:10.7554/eLife.34408
672 37. Bulik-Sullivan BK, Loh PR, Finucane HK, et al. LD Score regression
673 distinguishes confounding from polygenicity in genome-wide association studies. *Nat*
674 *Genet*. Mar 2015;47(3):291-5. doi:10.1038/ng.3211
675 38. Carter AR, Sanderson E, Hammerton G, et al. Mendelian randomisation for
676 mediation analysis: current methods and challenges for implementation. *Eur J*
677 *Epidemiol*. May 2021;36(5):465-478. doi:10.1007/s10654-021-00757-1

678 39. Cheng C, Spiegelman D, Li F. Estimating the natural indirect effect and the
679 mediation proportion via the product method. *BMC Med Res Methodol*. Nov 20
680 2021;21(1):253. doi:10.1186/s12874-021-01425-4
681 40. Cheng C, Spiegelman D, Li F. Is the Product Method More Efficient Than the
682 Difference Method for Assessing Mediation? *Am J Epidemiol*. Jan 6 2023;192(1):84-
683 92. doi:10.1093/aje/kwac144
684 41. Sobel ME. Asymptotic Confidence Intervals for Indirect Effects in Structural
685 Equation Models. *Sociological Methodology* 1982;
686 42. David P. MacKinnon CML, Jeanne M. Hoffman, Stephen G. West, and Virgil,
687 Sheets. A Comparison of Methods to Test Mediation and Other Intervening
688 Variable Effects. *Psychol Methods*. 2002;
689 43. Guo Y, Xu T, Luo J, et al. SMR-Portal: an online platform for integrative
690 analysis of GWAS and xQTL data to identify complex trait genes. *Nat Methods*. Feb
691 2025;22(2):220-222. doi:10.1038/s41592-024-02561-7
692 44. Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and
693 eQTL studies predicts complex trait gene targets. *Nat Genet*. May 2016;48(5):481-7.
694 doi:10.1038/ng.3538
695 45. Pietzner M, Wheeler E, Carrasco-Zanini J, et al. Mapping the proteo-genomic
696 convergence of human diseases. *Science*. Nov 12 2021;374(6569):eabj1541.
697 doi:10.1126/science.abj1541
698 46. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list
699 enrichment analysis and candidate gene prioritization. *Nucleic acids research*. Jul
700 2009;37(Web Server issue):W305-11. doi:10.1093/nar/gkp427

701 47. Liu B, Gloudemans MJ, Rao AS, Ingelsson E, Montgomery SB. Abundant
702 associations with gene expression complicate GWAS follow-up. *Nat Genet*. May
703 2019;51(5):768-769. doi:10.1038/s41588-019-0404-0
704 48. Loukil I, Mutch DM, Plourde M. Genetic association between FADS and
705 ELOVL polymorphisms and the circulating levels of EPA/DHA in humans: a scoping
706 review. *Genes Nutr*. Jun 6 2024;19(1):11. doi:10.1186/s12263-024-00747-4
707 49. Borges MC, Haycock PC, Zheng J, et al. Role of circulating polyunsaturated
708 fatty acids on cardiovascular diseases risk: analysis using Mendelian randomization
709 and fatty acid genetic association data from over 114,000 UK Biobank participants.
710 *BMC Med*. Jun 13 2022;20(1):210. doi:10.1186/s12916-022-02399-w
711 50. Kris-Etherton PM, Harris WS, Appel LJ, American Heart Association.
712 Nutrition C. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular
713 disease. *Circulation*. Nov 19 2002;106(21):2747-57.
714 doi:10.1161/01.cir.0000038493.65177.94
715 51. Allaire J, Couture P, Leclerc M, et al. A randomized, crossover, head-to-head
716 comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to
717 reduce inflammation markers in men and women: the Comparing EPA to DHA
718 (ComparED) Study. *Am J Clin Nutr*. Aug 2016;104(2):280-7.
719 doi:10.3945/ajcn.116.131896
720 52. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol
721 by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new
722 HMG-CoA reductase inhibitor. *Arterioscler Thromb Vasc Biol*. May 1995;15(5):678-
723 82. doi:10.1161/01.atv.15.5.678

724 53. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin
725 Therapy after Acute Coronary Syndromes. *N Engl J Med*. Jun 18 2015;372(25):2387-
726 97. doi:10.1056/NEJMoa1410489
727 54. Huijgen R, Sjouke B, Vis K, et al. Genetic variation inAPOB,PCSK9,
728 andANGPTL3in carriers of pathogenic autosomal dominant hypercholesterolemic
729 mutations with unexpected low LDL-Cl Levels. *Human Mutation*. 2012;33(2):448-
730 455. doi:10.1002/humu.21660
731 55. Luo F, Das A, Khetarpal SA, et al. ANGPTL3 inhibition, dyslipidemia, and
732 cardiovascular diseases. *Trends in Cardiovascular Medicine*. 2024;34(4):215-222.
733 doi:10.1016/j.tcm.2023.01.008
734 56. Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and Pharmacologic
735 Inactivation of ANGPTL3 and Cardiovascular Disease. *New England Journal of*
736 *Medicine*. 2017;377(3):211-221. doi:10.1056/NEJMoa1612790
737 57. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical
738 Outcomes in Patients with Cardiovascular Disease. *New England Journal of Medicine*.
739 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664
740 58. Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous
741 Familial Hypercholesterolemia. *New England Journal of Medicine*. 2020;383(8):711-
742 720. doi:10.1056/NEJMoa2004215
743 59. Chen G, Qian ZM, Zhang J, et al. Regular use of fish oil supplements and
744 course of cardiovascular diseases: prospective cohort study. *BMJ Med*.
745 2024;3(1):e000451. doi:10.1136/bmjmed-2022-000451
746 60. Borges MC, Haycock P, Zheng J, et al. The impact of fatty acids biosynthesis
747 on the risk of cardiovascular diseases in Europeans and East Asians: a Mendelian

748 randomization study. *Hum Mol Genet*. Nov 28 2022;31(23):4034-4054.
749 doi:10.1093/hmg/ddac153
750 61. Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous
751 Familial Hypercholesterolemia. *N Engl J Med*. Aug 20 2020;383(8):711-720.
752 doi:10.1056/NEJMoa2004215
753 62. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical
754 Outcomes in Patients with Cardiovascular Disease. *N Engl J Med*. May 4
755 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664
756 63. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA,
757 Thompson JR. Assessing the suitability of summary data for two-sample Mendelian
758 randomization analyses using MR-Egger regression: the role of the I^2 statistic. *Int J*
759 *Epidemiol*. Dec 1 2016;45(6):1961-1974. doi:10.1093/ije/dyw220
760 64. Nguyen K, Mitchell BD. A Guide to Understanding Mendelian
761 Randomization Studies. *Arthritis Care Res (Hoboken)*. Nov 2024;76(11):1451-1460.
762 doi:10.1002/acr.25400
763
764

765 **Figure legends**

766 **Figure 1 Flowchart of Study Design.**

767 **Figure 2 Effect of omega-3 on cardiovascular events (a) and related**
768 **metabolic traits (b) estimated across five mendelian randomization (MR)**
769 **methods.** nIVs, number of instrumental variables (IVs) used in the analysis.
770 SE, standard error of the effect estimate. The APSS algorithm employs
771 considerably fewer instrumental variables because it restricts analysis to
772 SNPs included in the HapMap 3 reference panel (See Methods).

773 **Figure 3 Effects of omega-3 on cardiovascular events with or without**
774 **inclusion of variants in the FADS gene cluster.** (a) Primary omega-3
775 GWAS derived from a multi-cohort study was used as the exposure. (b)
776 Secondary omega-3 GWAS derived from UK Biobank (2022) was used as the
777 exposure. The *FADS* gene cluster was defined as a region in hg19;
778 chr11:61,067,097–62,134,826. The Bonferroni-adjusted significance threshold
779 was set to be 0.00625 (0.05/8).

780 **Figure 4 Enhanced Lipid control is essential for omega-3's**
781 **cardiovascular protection.** a) The direct effect of omega-3 on coronary
782 artery disease by subsequently adjusting for variants associated with LDL-C,
783 triglycerides and both lipid traits. b) Mediation analysis of the effect of omega-
784 3 fatty acids on CAD risk through LDL-C. Red solid line illustrates the total
785 effect of genetically predicted omega-3 on CAD. Step 1 (yellow solid line)
786 represents the effect of omega-3 on LDL-C, and Step 2 (yellow solid line)
787 represents the effect of LDL-C on CAD. The green dashed line indicates the
788 indirect effect mediated by LDL-C. Indirect effect estimates of omega-3 on
789 CAD through LDL-C using 4 MR methods. Error bars represent 95% CIs
790 calculated using the Delta method (red) and Monte Carlo method (green).
791 Yellow triangles represent proportion of the indirect effect relative to the total
792 effect across 4 MR methods. c) Subgroup analyses from the STRENGTH and
793 REDUCE-IT trials showed that the protective effect of omega-3 appeared to
794 be associated with the intensity of LDL-C lowering therapy.

795 **Figure 5 Colocalization of protein QTLs (pQTLs) with genetic loci**
796 **associated with omega-3 levels.** Red dots show the results derived from the
797 primary omega-3 GWAS, and green dots represent the results based on the
798 secondary omega-3 GWAS. SE stands for Standard error.
799

800

801



Figure 1 Flowchart of Study Design

a)

Disease outcomes	Methods	nIVs	Beta	SE	*P*-value
CAD (2022) (181, 522 cases, 984, 168 controls)					
	IVW	131	0.065	0.010	1.83e−11
	MR Egger	131	0.037	0.018	4.16e−02
	Weighted mode	131	0.019	0.005	2.65e−04
	APSS	83	0.141	0.023	6.64e−10
	FADS (rs174564−A)	1	0.012	0.006	3.70e−02
CAD (2017) (34, 541cases, 261, 984 controls)					
	IVW	124	0.123	0.018	2.18e−12
	MR Egger	124	0.074	0.033	2.45e−02
	Weighted mode	124	0.052	0.010	2.87e−07
	APSS	82	0.244	0.038	1.61e−10
	FADS (rs174564−A)	1	0.036	0.012	2.00e−03
Myocardial Infarction (61, 505 cases, 577, 716 controls)					
	IVW	121	0.068	0.009	4.88e−13
	MR Egger	121	0.045	0.018	1.12e−02
	Weighted mode	121	0.036	0.006	1.03e−07
	APSS	82	0.128	0.020	7.03e−11
	FADS (rs174564−A)	1	0.022	0.008	4.20e−03
Heart Failure (47, 309 cases, 930, 014 controls)					
	IVW	123	0.019	0.004	1.16e−05
	MR Egger	123	0.027	0.008	1.65e−03
	Weighted mode	123	0.017	0.006	4.90e−03
	APSS	82	0.024	0.009	4.84e−03
	FADS (rs174564−A)	1	0.015	0.006	2.10e−02
Atrial Fibrillation (60, 620 cases, 970, 216 controls)					
	IVW	131	0.008	0.003	9.45e−03
	MR Egger	131	0.014	0.006	2.19e−02
	Weighted mode	131	0.010	0.005	4.12e−02
	APSS	83	0.011	0.006	7.22e−02
	FADS (rs174564−A)	1	0.011	0.006	6.50e−02
Stroke (40, 585 cases, 406, 111 controls)					
	IVW	121	0.018	0.006	1.40e−03
	MR Egger	121	0.019	0.011	8.48e−02
	Weighted mode	121	0.018	0.009	3.78e−02
	APSS	83	0.015	0.011	1.79e−01
	FADS (rs174564−A)	1	0.020	0.009	3.60e−02
Ischemic Stroke (4, 217 cases, 406, 111 controls)					
	IVW	121	0.019	0.006	7.51e−04
	MR Egger	121	0.022	0.011	4.60e−02
	Weighted mode	121	0.018	0.009	3.52e−02
	APSS	83	0.020	0.012	8.44e−02
	FADS (rs174564−A)	1	0.024	0.010	1.29e−02
Type 2 Diabetes (62, 892 cases, 596, 424 controls)					
	IVW	57	−0.010	0.012	3.97e−01
	MR Egger	57	−0.001	0.019	9.62e−01
	Weighted mode	57	0.025	0.008	3.71e−03
	APSS	65	−0.022	0.015	1.39e−01
	FADS (rs174564−A)	1	0.031	0.008	2.00e−04
Type 1 Diabetes (n = 181, 214 samples)					
	IVW	91	−0.012	0.011	2.97e−01
	MR Egger	91	0.003	0.020	8.67e−01
	Weighted mode	91	0.010	0.013	4.44e−01
	APSS	75	−0.031	0.017	6.91e−02
	FADS (rs174564−A)	1	0.026	0.015	8.00e−02



b)

Metabolic traits	Methods	nIVs	Beta	SE	*P*-value
Total Cholesterol (n = 1, 320, 016)					
	IVW	102	0.321	0.027	7.37e−33
	MR Egger	102	0.226	0.047	6.70e−06
	Weighted mode	102	0.147	0.004	3.55e−56
	APSS	60	0.458	0.057	1.55e−15
	FADS (rs174564−A)	1	0.163	0.005	1.85e−194
LDL−C (n = 1, 320, 016)					
	IVW	112	0.250	0.021	2.48e−33
	MR Egger	112	0.195	0.038	1.17e−06
	Weighted mode	112	0.148	0.005	1.59e−57
	APSS	68	0.330	0.044	9.00e−14
	FADS (rs174564−A)	1	0.168	0.006	3.11e−191
HDL−C (n = 1, 654, 960)					
	IVW	111	0.051	0.029	7.92e−02
	MR Egger	111	0.073	0.054	1.78e−01
	Weighted mode	111	0.157	0.005	9.01e−59
	APSS	67	−0.087	0.056	1.22e−01
	FADS (rs174564−A)	1	0.170	0.005	2.99e−243
Triglycerides (2021) (n = 1,320,016)					
	IVW	112	0.007	0.032	8.30e−01
	MR Egger	112	−0.169	0.058	4.16e−03
	Weighted mode	112	−0.182	0.006	8.69e−59
	APSS	65	0.079	0.048	9.88e−02
	FADS (rs174564−A)	1	−0.205	0.006	2.42e−288
Triglycerides (2022) (n = 361,194)					
	IVW	94	0.001	0.033	9.69e−01
	MR Egger	94	−0.196	0.056	6.80e−04
	Weighted mode	94	−0.176	0.009	3.61e−33
	APSS	69	0.009	0.052	8.64e−01
	FADS (rs174564−A)	1	−0.203	0.010	1.03e−83
ApoB (n = 136, 016)					
	IVW	90	0.271	0.032	2.09e−17
	MR Egger	90	0.109	0.053	4.40e−02
	Weighted mode	90	0.091	0.013	2.61e−10
	APSS	51	0.284	0.060	2.01e−06
	FADS (rs174564−A)	1	0.093	0.017	5.61e−08
ApoA (n = 323, 833)					
	IVW	23	0.074	0.068	2.76e−01
	MR Egger	23	−0.03	0.166	8.58e−01
	Weighted mode	23	0.018	0.037	6.36e−01
	APSS	50	−0.101	0.066	1.27e−01
	FADS (rs174550−T)	1	0.169	0.011	1.23e−52
Hypertension (28, 391 cases, 28, 246 controls)					
	IVW	121	0.008	0.014	5.53e−01
	MR Egger	121	−0.033	0.026	2.03e−01
	Weighted mode	121	−0.028	0.023	2.15e−01
	APSS	81	0.033	0.024	1.61e−01
	FADS (rs174564−A)	1	−0.028	0.026	2.88e−01



Figure 2 Effect of omega-3 on cardiovascular events (a) and related metabolic traits (b) estimated across five mendelian randomization (MR) methods. nIVs, number of instrumental variables (IVs) used in the analysis. SE, standard error of the effect estimate. The APSS algorithm employs considerably fewer instrumental variables because it restricts analysis to SNPs included in the HapMap 3 reference panel (See Methods).



Figure 3 Effects of omega-3 on cardiovascular events with or without inclusion of variants in the *FADS* gene cluster. (a) Primary omega-3 GWAS derived from a multi-cohort study was used as the exposure. (b) Secondary omega-3 GWAS derived from UK Biobank (2022) was used as the exposure. The *FADS* gene cluster was defined as a region in hg19: chr11:61,067,097–62,134,826. The Bonferroni-adjusted significance threshold was set to be 0.00625 (0.05/8)

a)

Exposure	Outcome	Beta	SE	*P*- Value
Non-adjusted				
Primary omega-3 (2024)	CAD (2022)	0.065	0.010	1.83e-11
Primary omega-3 (2024)	CAD (2017)	0.123	0.018	2.18e-12
Secondary omega-3 (2022)	CAD (2022)	0.031	0.008	1.21e-04
Secondary omega-3 (2022)	CAD (2017)	0.066	0.012	1.26e-07
Combined		**0.055**	**0.005**	**0**
LDL-C-adjusted				
Primary omega-3 (2024)	CAD (2022)	-0.049	0.023	3.78e-02
Primary omega-3 (2024)	CAD (2017)	-0.018	0.025	4.67e-01
Secondary omega-3 (2022)	CAD (2022)	-0.026	0.020	1.91e-01
Secondary omega-3 (2022)	CAD (2017)	-0.010	0.021	6.18e-01
Combined		**-0.025**	**0.011**	**2.25e-02**
Triglycerides-adjusted				
Primary omega-3 (2024)	CAD (2022)	0.165	0.021	8.56e-15
Primary omega-3 (2024)	CAD (2017)	0.179	0.022	3.98e-16
Secondary omega-3 (2022)	CAD (2022)	0.060	0.019	1.51e-03
Secondary omega-3 (2022)	CAD (2017)	0.081	0.021	8.63e-05
Combined		**0.116**	**0.010**	**0**
LDL-C and Triglycerides-adjusted				
Primary omega-3 (2024)	CAD (2022)	-0.072	0.021	4.85e-04
Primary omega-3 (2024)	CAD (2017)	-0.052	0.022	1.68e-02
Secondary omega-3 (2022)	CAD (2022)	-0.073	0.018	4.10e-05
Secondary omega-3 (2022)	CAD (2017)	-0.065	0.019	5.89e-04
Combined		**-0.066**	**0.010**	**1.28e-11**



b)



c)



Figure 4 Enhanced Lipid control is essential for omega-3's cardiovascular protection. a) The direct effect of omega-3 on coronary artery disease by subsequently adjusting for variants associated with LDL-C, triglycerides and both lipid traits. b) Mediation analysis of the effect of omega-3 fatty acids on CAD risk through LDL-C. Red solid line illustrates the total effect of genetically predicted omega-3 on CAD. Step 1 (yellow solid line) represents the effect of omega-3 on LDL-C, and Step 2 (yellow solid line) represents the effect of LDL-C on CAD. The green dashed line indicates the indirect effect mediated by LDL-C. Indirect effect estimates of omega-3 on CAD through LDL-C using 4 MR methods. Error bars represent 95% CIs calculated using the Delta method (red) and Monte Carlo method (green). Yellow triangles represent proportion of the indirect effect relative to the total effect across 4 MR methods. c) Subgroup analyses from the STRENGTH and REDUCE-IT trials showed that the protective effect of omega-3 appeared to be associated with the intensity of LDL-C lowering therapy.

Colocalization	β_{SMR}	SE_{SMR}	P_{SMR}	P_{HEIDI}
GCKR				
Primary omega−3 (2024)	−0.224	0.016	6.56e−45	0.097
Secondary omega−3 (2022)	−0.258	0.017	4.94e−55	0.055
ANGPTL3				
Primary omega−3 (2024)	0.197	0.018	1.22e−27	0.898
Secondary omega−3 (2022)	0.254	0.019	3.85e−40	0.998
PCSK9				
Primary omega−3 (2024)	0.192	0.020	1.15e−21	0.119
Secondary omega−3 (2022)	0.107	0.018	4.65e−09	0.750
TIMD4				
Primary omega−3 (2024)	−0.153	0.021	6.41e−13	0.030
Secondary omega−3 (2022)	−0.126	0.021	9.51e−10	0.503
APOB				
Primary omega−3 (2024)	0.488	0.076	1.57e−10	0.153
Secondary omega−3 (2022)	0.334	0.059	1.74e−08	0.599



Figure 5 Colocalization of protein QTLs (pQTLs) with genetic loci associated with omega-3 levels. Red dots show the results derived from the primary omega-3 GWAS, and green dots represent the results based on the secondary omega-3 GWAS. SE stands for Standard error.